Emmaus Life Sciences Short Interest Ratio and Short Volume

Short interest is the volume of Emmaus Life Sciences shares that have been sold short but have not yet been closed out or covered. As of January 29th, traders have sold 2,400 shares of EMMA short.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Emmaus Life Sciences currently has a short interest ratio of 1.0.

Emmaus Life Sciences saw a drop in short interest in January. As of January 29th, there was short interest totaling 2,400 shares, a drop of 11.1% from the previous total of 2,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Emmaus Life Sciences' shares are currently sold short. Here is how the short interest of companies in the industry of "miscellaneous health & allied services, not elsewhere classified" compare to Emmaus Life Sciences: Fresenius Medical Care AG & Co. KGaA (0.06%), DaVita Inc. (2.39%), Progyny, Inc. (4.98%), Tivity Health, Inc. (19.57%), Ontrak, Inc. (31.98%), SOC Telemed, Inc. (5.10%), Viemed Healthcare, Inc. (3.75%), Baudax Bio, Inc. (6.37%), GreenVision Acquisition Corp. (0.06%), and Cryo-Cell International, Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon Plc ($5.34 billion), Charter Communications, Inc. ($5.03 billion), ViacomCBS Inc. ($4.99 billion), DuPont de Nemours, Inc. ($4.72 billion), Analog Devices, Inc. ($4.57 billion), Snap Inc. ($3.87 billion), Moderna, Inc. ($3.58 billion), Futu Holdings Limited ($2.75 billion), Snowflake Inc. ($2.43 billion), and Palantir Technologies Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling EMMA is an investing strategy that aims to generate trading profit from Emmaus Life Sciences as its price is falling. To short Emmaus Life Sciences stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Emmaus Life Sciences will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Emmaus Life Sciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EMMA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EMMA, twice per month. The most recent reporting period available is January, 29 2021.